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It has been well described that carbohydrate antigen (CA) 19.9 is synthesized by epithelial cells of the gastrointestinal tract, pancreatic duct and biliary tree. The 
CA 19.9 antigen is commonly used as a tumor marker for malignancies of the pancreas and biliary tract. It has been suggested that high levels of CA 19-9 (> 
300 U/ml) antigen have a strong correlation with malignant biliary pathology. In this paper, we present a patient with extremely elevated levels of tumor marker 
(CA 19-9 >4000) resulting from Mirizzi’s Syndrome.
Introduction Discussion
  
•  Elevations in CA 19-9 levels have traditionally been 
associated with malignancies of the biliary tract and 
pancreas. 
•  There is growing data, however, demonstrating elevated 
levels of CA 19-9 in benign biliary pathology, obstructive 
and infectious. 
•  Typically, CA 19-9 levels greater than 300 U/ml are used 
as the upper limits of normal for benign processes.
•  To our knowledge, there are only three other reports 
of CA 19-9 elevations of this magnitude secondary to 
Mirizzi’s Syndrome.
•  Helling et. al described a similar case of Mirizzi’s 
Syndrome with CA 19-9 levels above 6000 U/ml.1 In 
2006 and 2007, 2 additional cases were reported with 
CA 19-9 levels of >5000 U/ml and >16,000 U/ml.
•  ERCP was helpful when the common bile duct could be 
cannulated, but still did not provide definitive diagnoses.  
•  EUS was not mentioned in any of these case reports 
and the culprit gallstones were discovered only 
intraoperatively during cholecystectomy or, in one case, 
laparotomy for open liver biopsy. 
•  EUS can be a useful tool to evaluate for gallstones 
impinging on the common bile duct to further distinguish 
between malignant etiology and Mirrizzi syndrome 
which can be difficult to visualize on transabdominal 
ultrasound.
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Our patient was a 51 year old male with a several week history of epigastric pain who presented with new onset jaundice, tea-colored urine and light stools 
of one week duration. Total bilirubin was elevated at 19.6. Initial abdominal CT scan revealed markedly dilated intrahepatic and common bile ducts, the 
latter measuring 1.5 cm. No stones or masses were visualized. CA 19-9 levels were elevated at 4258. Given his presentation, clinical suspicion was high for 
a biliary tract malignancy. Specifically, there was concern for early pancreatic cancer or a lesion at the Ampulla of Vater. The patient underwent Endoscopic 
Ultrasound Examination which demonstrated a large stone at the junction of the cystic duct and common bile duct. The bile duct was swept without evidence 
of stones. A wire was then advanced into the cystic duct, however the stone could not be successfully retrieved. A stent was placed in the cystic duct but the 
magnitude of the stone was such that subsequent cholangiogram did not demonstrate cystic duct filling beyond the level of obstruction. The patient underwent 
cholecystostomy tube placement and was continued on antibiotics. He improved clinically with gradual decrease of his hyperbilirubinemia and undwerent a 
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Fig. 1	Marked	dilation	of	the	intrahepatic	ducts. Fig. 2	Distended	gallbladder. Fig. 3	Stone	visualized	in	the	bile	vs	cystic	duct. Fig. 4	Dilated	common	bile	duct.
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